Formulation and optimization of captopril sublingual tablet using D-optimal design

Iranian Journal of Pharmaceutical Research

Volumn 7, Issue 4, 2008, Pages 259-267

  Bolourtchian, Noushin ^a,b   Hadidi, Naghmeh ^a   Foroutan, Seyed Mohsen ^a,b   Shafaghi, Bijan ^a  

^a SHAHID BEHESHTI UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Captopril; D optimal mixture design; Optimization; Sublingual tablet

Indexed keywords

ASPARTAME; CAPTOPRIL; LACTOSE; MAGNESIUM STEARATE; POVIDONE; STARCH GLYCOLATE SODIUM; TALC;

ARTICLE; D OPTIMAL MIXTURE DESIGN; DRUG ADMINISTRATION ROUTE; DRUG DESIGN; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; IN VITRO STUDY; MATHEMATICAL COMPUTING; PHYSICAL CHEMISTRY; PROCESS DESIGN; PROCESS OPTIMIZATION; TABLET COMPRESSION; TABLET DISINTEGRATION TIME; TABLET FORMULATION; TABLET FRIABILITY; TABLET HARDNESS;

EID: 67549117522     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sweetman SC. (ed.) Martinedale, the Complete Drug Reference. 35th ed., Pharmaceutical Press, London (2007) 1112-1113
2. Ohman KP, Kagedal B, Larsson R and Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J. Cardiovasc. Pharmacol. (1985) 7: S20-S24
3. Al-Furaih TA, McElnay JC, Elborn JS, Rusk R, Scott MG, McMahon J and Nicholls DP. Sublingual captopril-a pharmacokinetic and pharmacodynamic evaluation. Eur. J. Clin. Pharmacol. (1991) 40: 393-398
4. Chetty DJ, Chen LH and Chien YW. Characterization of captopril sublingual permeation: determination of preferred routes and mechanisms. J. Pharm. Sci. (2001) 90: 1868-1877
5. Harris D and Robinson JR. Drug delivery via the mucous membranes of the oral cavity. J. Pharm. Sci. (1992) 81: 1-10
6. Wu SG, Lin SL, Shiao WY, Huang HW, Lin CF and Yang YH. Comparison of sublingual captopril, nifedipine and prazosin in hypertensive emergencies during hemodialysis. Nephron (1993) 65: 284-287
7. Longhini C, Ansani L, Musacci G, Mele D, Vaccari M, Baracca E and Sgobino P. The effect of captopril on peripheral hemodynamics in patients with essential hypertension: comparison between oral and sublingual administration. Cardiovasc. Drugs Ther. (1990) 4: 751-754
8. Angeli P, Chiesa M, Caregaro L, Merkel C, Sacerdoti D, Rondana M and Gatta A. Comparison of sublingual captopril and nifedipine in immediate treatment of hypertensive emergencies; a randomized, single-blind clinical trial. Arch. Intern. Med. (1991) 151: 678-682
9. McElnay JC, Al-Furaih TA, Hughes CM, Scott MG and Nicholls DP. A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. Eur. J. Clin. Pharmacol. (1996) 49: 471-476
10. Mura P, Furlanetto S, Cirri M, Maestrelli F, Marras AM and Pinzauti S. Optimization of glibenclamide tablet composition through the combined use of differential scanning calorimetry and D-optimal mixture experimental design. J. Pharm. Biomed. Anal. (2005) 37: 65-71
11. Hwang RH and Kowalski DL. Design of experiments for formulation development. Pharm. Technol. (2005) Dec. 1
12. Armstrong NA. Pharmaceutical Experimental Design and Interpretation. 2nd ed., Taylor & Francis, London (2006) 189-205
13. Croarkin C, Filliben JJ, Guthrie WF, Heckert A, Tobias P, Prins J, Zey C, Hembree B and Spagon P. Engineering Statistics Handbook. NIST/ SEMATECH e-Handbook of Statistical Methods. Available from: http://www.itl.nist.gov/div898/handbook/, National Institute of Standard and Technology (2003)
14. Melas VB. Functional Approach to Optimal Experimental Design. Springer, New York (2006) 197-228
15. Eriksson L, Johansson E and Wikstrom C. Mixture design: design generation, PLS analysis and model usage. Chemomet. Intell. Lab. Syst. (1998) 43: 1-24
16. El-Malah Y, Nazzal S and Khanfar NM. D-optimal mixture design: optimization of ternary matrix blends for controlled zero-order drug release from oral dosage forms. Drug Dev. Ind. Pharm. (2006) 32: 1207-1218
17. Patel SS, Ray S and Thakur RS. Formualtion and evaluation of floating drug delivery system containing clarithromycin for Helicobacter pylori. Acta Pol. Pharm. (2006) 63: 53-61
18. Gonnissen Y, Gonealves SI, Remon JP and Vervaet C. Mixture design applied to optimize a directly compressible powder produced via cospray drying. Drug Dev. Ind. Pharm. (2008) 34: 248-257
19. Bodea A and Leucuta SE. Optimization of hydrophilic matrix tablets using a D-optimal design. Int. J. Pharm. (1997) 153: 247-255
20. Cornell JA. Designs Models and the Analysis of Mixture Data. 2nd ed. J. Wiley and sons, New York (1990) 188-236
21. Rowe RC, Sheskey PJ and Weller PJ. (eds.) Handbook of Pharmaceutical Excipients. 4th ed. Pharmaceutical Press and American Pharmaceutical Association, London (2003) 508, 581
22. United States Pharmacopeia, National Formulary USP29/NF24. The United States Pharmacopeial Convention, Rockville (2006) 367
23. Ugarkovic SJ. Sublingual Oral Dosage Form. US Patent no. 6572891, (2000)
24. Klancke J. Dissolution testing of orally disintegrating tablets. Diss. Technol. (2003) 10(2): 6-8